Organon & Co. (NYSE:OGN) Receives Average Recommendation of “Hold” from Brokerages

Organon & Co. (NYSE:OGN) has been assigned an average recommendation of “Hold” from the seven ratings firms that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, three have given a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $20.80.

OGN has been the subject of several recent research reports. Barclays cut their target price on shares of Organon & Co. from $26.00 to $24.00 and set an “overweight” rating for the company in a research report on Friday, February 14th. TD Cowen upgraded shares of Organon & Co. to a “hold” rating in a research report on Wednesday, January 15th. Finally, Morgan Stanley cut their target price on shares of Organon & Co. from $17.00 to $16.00 and set an “equal weight” rating for the company in a research report on Friday, February 14th.

Hedge Funds Weigh In On Organon & Co.

Large investors have recently added to or reduced their stakes in the company. Commerce Bank lifted its holdings in shares of Organon & Co. by 5.5% in the third quarter. Commerce Bank now owns 12,168 shares of the company’s stock worth $233,000 after buying an additional 637 shares in the last quarter. MassMutual Private Wealth & Trust FSB lifted its holdings in shares of Organon & Co. by 32.4% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 2,749 shares of the company’s stock worth $41,000 after buying an additional 672 shares in the last quarter. Treasurer of the State of North Carolina lifted its holdings in shares of Organon & Co. by 0.6% in the fourth quarter. Treasurer of the State of North Carolina now owns 113,120 shares of the company’s stock worth $1,688,000 after buying an additional 710 shares in the last quarter. Beam Wealth Advisors Inc. lifted its holdings in shares of Organon & Co. by 3.9% in the fourth quarter. Beam Wealth Advisors Inc. now owns 18,888 shares of the company’s stock worth $282,000 after buying an additional 717 shares in the last quarter. Finally, HighTower Advisors LLC lifted its holdings in shares of Organon & Co. by 0.5% in the fourth quarter. HighTower Advisors LLC now owns 163,440 shares of the company’s stock worth $2,439,000 after buying an additional 855 shares in the last quarter. Hedge funds and other institutional investors own 77.43% of the company’s stock.

Organon & Co. Stock Performance

Shares of NYSE OGN opened at $15.72 on Tuesday. The firm has a 50 day moving average of $15.44 and a 200 day moving average of $16.85. The company has a current ratio of 1.70, a quick ratio of 1.21 and a debt-to-equity ratio of 17.73. The firm has a market capitalization of $4.05 billion, a price-to-earnings ratio of 4.72, a price-to-earnings-growth ratio of 0.90 and a beta of 0.76. Organon & Co. has a 12-month low of $13.87 and a 12-month high of $23.10.

Organon & Co. (NYSE:OGN) last announced its earnings results on Thursday, February 13th. The company reported $0.83 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.09). The business had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $1.57 billion. Organon & Co. had a net margin of 13.49% and a return on equity of 431.62%. On average, research analysts anticipate that Organon & Co. will post 3.68 earnings per share for the current year.

Organon & Co. Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 13th. Shareholders of record on Monday, February 24th will be issued a dividend of $0.28 per share. This represents a $1.12 annualized dividend and a yield of 7.13%. The ex-dividend date of this dividend is Monday, February 24th. Organon & Co.’s dividend payout ratio is currently 33.63%.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.